- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03540407
Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma.
January 22, 2020 updated by: Catalysis SL
Efficacy of the Oncoxin-Viusid® Oral Solution in Reducing the Adverse Reactions of Chemotherapy and Radiotherapy in Patients Diagnosed With Cervical Cancer and Endometrial Adenocarcinoma.
The purpose of this study is to evaluate the efficacy of oral solution Oncoxin-Viusid in the reduction of acute toxicity of Radiotherapy (RTP) and Chemotherapy (QTP) in patients with histological diagnosis of cervical cancer and endometrial adenocarcinoma.
This is a phase II, prospective, randomized and double blind clinical trial, which will include 66 patients assigned to 2 treatment arms: 33 patients will receive conventional treatment, plus a placebo of the nutritional supplement and another 33 patients will receive along with the conventional treatment the Oncoxin-Viusid nutritional supplement produced by the Catalysis Laboratories of Spain.
Patients will receive oral treatment throughout the onco-specific treatment and up to 3 weeks after completion.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Patients will be evaluated clinically and hematological at the beginning of the treatment, before each cycle of treatment with QTP / RTP, at month, two and three months after the end of the treatment with follow-up every three months for 1 year.
The self-perceived quality of life related to health will be assessed by means of the EORTC questionnaires (QLQ-C30 and the specific questionnaire QLQ-CX24) at the beginning and a year after completing the treatment.
The toxicity to the research product will be described according to Common Criteria of Terminology for the Report of Adverse Events (CTCAE version 4) and the tolerance to onco-specific treatment.
It is expected that with the joint administration of the research product, the patients will have a better tolerance to the treatment of QTP / RTP with a decrease of the interruptions by toxicity in 25% and will preserve a better quality of life.
Study Type
Interventional
Enrollment (Anticipated)
66
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
La Habana, Cuba, 10400
- Ramón González Coro Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Patients with histological confirmation of cervical cancer and adenocarcinoma of the endometrium that are treated with chemotherapy and ionizing radiation.
- Patient with age equal to or greater than 18 years and up to 80 years.
- Patients who do not present decompensated concurrent diseases at the time of diagnosis that prevent or contraindicate the application of treatment with chemo-radiotherapy.
- Informed consent to participate in the investigation.
- Patients with an ECOG <or equal to 3.
Exclusion Criteria:
- Patients with a history of renal failure that contraindicates the administration of cisplatin.
- Concomitant diseases unbalanced at the time of diagnosis or during the application of treatment.
- Patients with an ECOG> 3.
- Pregnant or lactating women.
- Patients who are receiving another research product.
- Patients who do not show consent to participate in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Oncoxin-Viusid®
will receive the Oncoxin-Viusid® (oral solution) concomitant to the onco-specific treatment.
|
Administration of the Oncoxin-Viusid® oral solution 25 mL three times a day during the concurrent Radiotherapy and Chemotherapy treatment and up to 3 weeks after the end of the onco-specific treatment
|
PLACEBO_COMPARATOR: Placebo
will receive a Placebo concomitant to the onco-specific treatment
|
Administration of the Oncoxin-Viusid® oral solution placebo 25 ml three times a day during the concurrent Radiotherapy and Chemotherapy treatment and up to 3 weeks after the end of the onco-specific treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity of chemotherapy and radiotherapy in patients diagnosed with cervical cancer and endometrium adenocarcinoma.
Time Frame: 3 months
|
Patients diagnosed with cervical cancer and adenocarcinoma of the endometrium usually have varying degrees of malnutrition and immunodeficiencies; they are carriers of oncogenic virus infections, and present deterioration of their general state, depression-anxiety and socio-economic dysfunctions.
Oncospecific treatment's toxicity is measured according to Common Criteria of Terminology for the Report of Adverse Events (CTCAE version 4).
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
quality of life
Time Frame: 3 months
|
Self-perceived quality of life related to health through the EORTC test QLQ-C30 at the beginning and at the end of the treatment.
|
3 months
|
Reduce hospital costs
Time Frame: 3 months
|
Reduce hospital costs by being unnecessary or decreasing, the use of concomitant support treatments that counteract the adverse effects caused by these, hospitalization for the treatment of complications secondary to the treatment of QTP / RTP and the use of antibiotics in cases of neutropenia / leukopenia and sepsis added, very frequent in these patients.
|
3 months
|
Quality of life
Time Frame: 3 months
|
Self-perceived quality of life related to health through the EORTC test QLQ-CX24 at the beginning and at the end of the treatment
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Raiza Ruiz Llorente, Dr., Ramón González Coro Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 7, 2015
Primary Completion (ACTUAL)
February 1, 2019
Study Completion (ACTUAL)
September 30, 2019
Study Registration Dates
First Submitted
May 3, 2018
First Submitted That Met QC Criteria
May 16, 2018
First Posted (ACTUAL)
May 30, 2018
Study Record Updates
Last Update Posted (ACTUAL)
January 23, 2020
Last Update Submitted That Met QC Criteria
January 22, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OOS-CANCER-3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Carcinoma Stage II
-
National Cancer Institute (NCI)CompletedStage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Stage IV Endometrial Carcinoma | Stage I Ovarian Epithelial Cancer | Stage II Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Stage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage... and other conditionsUnited States
-
University of WashingtonNational Cancer Institute (NCI); National Institutes of Health (NIH)TerminatedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Cervical Undifferentiated Carcinoma | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage... and other conditionsUnited States, Hong Kong, Canada
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Sarcoma | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus Cancer | Recurrent Cervical Carcinoma | Stage III Uterine Sarcoma | Stage IV Uterine Sarcoma | Stage I Uterine... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IB2 Cervical Cancer AJCC v6 and v7 | Stage II Cervical Cancer AJCC v7 | Stage IIA Cervical Cancer AJCC v7 | Stage IIB Cervical Cancer AJCC v6 and v7 | Stage IIIB Cervical... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage IB2 Cervical Cancer AJCC v8 | Stage II Cervical Cancer AJCC v8 | Stage IIA Cervical Cancer AJCC v8 | Stage IIA1 Cervical Cancer AJCC v8 | Stage IIA2 Cervical Cancer AJCC v8 | Stage IIB Cervical Cancer AJCC v8 | Stage III Cervical Cancer AJCC v8 | Stage IIIA Cervical Cancer AJCC v8 | Stage IIIB... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer... and other conditionsUnited States
-
UNICANCERTerminatedAdenocarcinoma | Squamous Cell Carcinoma | Stage IB2 Cervical Cancer | Adenosquamous Carcinoma | Stage II Cervical CancerFrance
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Stage IB2 Cervical Cancer AJCC v8 | Stage II Cervical Cancer AJCC v8 | Stage IIA Cervical Cancer AJCC v8 | Stage IIA1 Cervical Cancer AJCC v8 | Stage IIA2 Cervical Cancer AJCC v8 | Stage IIB Cervical Cancer... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyActive, not recruitingCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Advanced Vaginal Adenocarcinoma | Advanced Vaginal Adenosquamous Carcinoma | Advanced Vaginal Squamous Cell Carcinoma | Cervical Squamous Cell Carcinoma | Stage IB2 Cervical Cancer AJCC v6 and v7 | Stage II Cervical Cancer AJCC v7 | Stage... and other conditionsUnited States, Canada, Puerto Rico
Clinical Trials on Oncoxin-Viusid®
-
Catalysis SLCompleted
-
Clinical Research Organization, Dhaka, BangladeshUnknownHepatocellular CarcinomaBangladesh
-
Catalysis SLCompletedCutaneous Melanoma, Stage II | Cutaneous Melanoma, Stage III | Malignant Cutaneous MelanomaCuba
-
Catalysis SLCompletedPapillomavirus Infections | Papilloma Viral Infection | Esophageal Viral Wart | Esophageal Verrucous CarcinomaCuba
-
Catalysis SLCompletedMucositis OralRussian Federation
-
Catalysis SLCompletedNon-small Cell Lung Cancer Stage III | Gastric Cancer Stage III | Gastric Cancer Stage II | Non-small Cell Lung Cancer Stage IIKazakhstan, Russian Federation
-
Catalysis SLCompletedDigestive System Diseases | Endocrine System Diseases | Digestive System Neoplasms | Endocrine Gland Neoplasms | Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Diseases | Advanced Cancer | Adenocarcinoma of the PancreasCuba
-
Catalysis SLRecruitingNeoplasms | Carcinoma | Neoplasia; Intraepithelial, Cervix | Glandular Neoplasms | Epithelial NeoplasmCuba